Acetylcysteine Amide

3 trials 1 recruiting RRespiratory

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

2 Countries

Phase II

Phase II: 3

Indications tested

Cerebral amyloid angiopathy 2

Sponsors using this IMP

Arctic Therapeutics ehf. 3

All trials

3 total

Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Not authorised

2023-503969-36-00 Phase II 1 country Arctic Therapeutics ehf.
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects with Alzheimer’s Disease (AD) Recruiting

2024-519497-39-00 Phase II 2 countries Arctic Therapeutics ehf.
Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Ended

2023-503969-36-01 Phase II 1 country Arctic Therapeutics hf.

Showing 1–3 of 3 trials

← All drugs A–Z